Tour Hekla

Company snapshot

La Tour Hekla conçue par Jean Nouvel, écrin de modernité en plein coeur de la Défense et symbole de l’excellence française. La Tour Hekla est portée par Hines, AG Real Estate, Amundi Immobilier, et Primonial REIM #FutureInFrance

• 27 active pipeline program(s) linked via ClinicalTrials.gov.
• 27 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Tour Hekla. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Tour Hekla.

1. Jun 8, 2026 Clinical update

   DR240305 — Approved

2. Jun 8, 2026 Clinical update

   DR230070 — Phase 2

3. Jun 8, 2026 Clinical update

   OPDIVO for Unresectable locally advanced o… — Phase 2

4. Jun 8, 2026 Clinical update

   DR220204 — Phase 2

5. Jun 8, 2026 Clinical update

   KALINOX 50%/50% for Treatment of suicidal ideation — Phase 2

View all clinical trial activity →

• What is Tour Hekla?

  Tour Hekla is a pharma organization headquartered in EU. Primary therapeutic focus areas include Muscle-invasive bladder cancer (MIBC), Acute ischaemic stroke due to basilar artery occlusion., Thrombotic episodes in superficial venous malformations in children, 1st line treatment

• Is Tour Hekla publicly traded?

  Tour Hekla appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Tour Hekla develop or market?

  We link 71 drug profile(s) where Tour Hekla is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/tour-hekla#company-drugs.

• What are the latest developments for Tour Hekla?

  In the last 12 months our linked public records show 27 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Tour Hekla focus on?

  Tour Hekla focuses on Muscle-invasive bladder cancer (MIBC), Acute ischaemic stroke due to basilar artery occlusion., Thrombotic episodes in superficial venous malformations in children based on our analysis of their pipeline programs and drug development activities.